BP Share News (BP.)

(Adds U.S. Bank stocks, RCS Capital, Skullcandy, Esperion, oildriller stocks, Boston scientific, Cytokinetics, China SouthernAirlines, NV5 Holdings; updates oil stocks) (For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)

Energy sector stocks led a broad selloff on Wall Street onMonday as crude prices fell to fresh five-and-a-half-year lowsand a strong dollar also weighed on other commodities. The DowJones industrial average was down 1.80 percent at17,511.22, the S&P 500 was down 1.85 percent at 2,020.19and the Nasdaq Composite was down 42.12 points, or 0.89percent, to 4,684.70.

** BANK OF AMERICA CORP, $17.359, -3.02 pct

** JPMORGAN CHASE & CO, $60.63, -2.98 pct

** GOLDMAN SACHS GROUP INC, $188.3, -3.14 pct

** CITIGROUP INC, $52.56, -3.13 pct

Shares of major U.S. banks were down in a broad selloff ledby energy stocks. "Traders know where they don't want to beinvested, before identifying the next buying opportunity," saidGordon Charlop, a managing director at Rosenblatt Securities inNew York.

** MORGAN STANLEY, $37.27, -3.72 pct

The bank said an employee stole data from up to 10 percentof its wealth management clients, including account names andnumbers, but there was no evidence of economic loss.

** RCS CAPITAL CORP, $12.6, +2.86 pct

The retail brokerage's wholesale broker dealer subsidiariesraised $9.7 billion in sales last year, despite salessuspensions. RCS Capital said it remained the securitiesindustry leader in raising money for non-traded investmentprograms.

Citigroup added RCS to its U.S. focus list.

** SKULLCANDY INC, $9.95, +10.19 pct

Jefferies upgraded the headphone maker's stock to "buy" from"hold", and raised its price target to $11 from $9. "We believe(the company) is better positioned in the competitive landscapetoday with sharper pricing, cleaner and more strategicdistribution and a more focused retail strategy to drive pricingpower and sales," Jefferies analysts said.

** ESPERION THERAPEUTICS INC, $44.88, +8.85 pct

JMP Securities analyst Jason Butler raised his price targeton the drugmaker's stock to $75 from $53, citing minimal risk ofnegative results from two-year carcinogenicity studies of thecompany's cholesterol drug, ETC-1002.

** ROYAL DUTCH SHELL PLC, $63.85, -4.67 pct

** TOTAL SA, $47.86, -6.45 pct

** BP PLC, $36.198, -5.04 pct

** STATOIL ASA, $16.47, -5.45 pct

** EXXON MOBIL CORP, $90.07, -2.97 pct

** CHEVRON CORP, $107.99, -4.08 pct

** PETROLEO BRASILEIRO PETROBRAS SA, $6.099, -9.78pct

** LAREDO PETROLEUM INC, $9.42, -13.58 pct

** BAYTEX ENERGY CORP, $14.46, -14.03 pct

** WHITING PETROLEUM CORP, $29.1, -12.32 pct

Oil and gas producers down after prices dropped to freshfive-and-a-half-year lows on concerns of supply glut andlackluster demand. Russia's oil output hit a post-Soviet highlast year, Iraq's oil exports were at their highest since 1980in December.

** PRECISION DRILLING CORP SHARES, $6.4, -10.24 pct

** PATTERSON-UTI ENERGY INC, $15.6, -6.31 pct

** NABORS INDUSTRIES LTD, $11.87, -4.96 pct

** HELMERICH & PAYNE INC, $65.02, -3.45 pct

** DIAMOND OFFSHORE DRILLING INC, $34.58, -7.12 pct

** SEADRILL LTD, $10.84, -9.74 pct

** TRANSOCEAN LTD, $16.79, -7.34 pct

** ENSCO PLC, $28.31, -6.17 pct

Oil drillers' shares were also pulled down by sliding oilprices. Oil prices have been dipping on concerns of a supplyglut and lackluster demand, losing more than half their valuesince a peak in June last year.

** BOSTON SCIENTIFIC CORP, $13.85, +4.77 pct

J.P. Morgan upgraded rating on the medical device maker'sstock to "overweight" from "neutral" and raised its price targetto $17.50 from $14.50. The company's performance were expectedto improve in the coming months with investors anticipating astrong 2015 and an even better 2016, driven by new products andsignificant margin expansion, analysts said in a note.

** CYTOKINETICS INC, $7.615, +3.32 pct

The drug developer said it would initiate mid-stage trial onits spinal muscle atrophy drug along with partner AstellasPharma Inc later this year.

Roth Capital analysts said extended collaboration provided a"strong cash runway".

** CHINA SOUTHERN AIRLINES CO LTD, $25.115, +7.61pct

The Chinese airline operator's US-listed shares were amongthe top percentage gainers on the NYSE. AerCap Holdings NV to lease 24 Airbus A320neo aircraft to China SouthernAirlines. AerCap's subsidiary, AeroTurbine, to buy four oldervintage aircraft from China Southern Airlines.

** NV5 HOLDINGS INC, $12.23, -6.93 pct

The engineering and consulting services provider said publicwarrant holders can convert all 412,414 outstanding warrantsinto shares. Each warrant can be exercised at purchase price of$7.80 per share. NV5 had 5.75 million shares outstanding as ofNov. 9, according to Thomson Reuters data.

** CLEANTECH SOLUTIONS INTERNATIONAL INC, $3.651,+7.38 pct

The Chinese maker of components for solar and wind energyindustries said it received $13 million orders in December fromChinese state-owned company based in Xinjiang to supplyequipment for large scale chemical project.

** GILEAD SCIENCES INC, $96.8, +1.99 pct

** ABBVIE INC, $64.35, -2.34 pct

** CVS HEALTH CORP, $94.02, -1.14 pct

CVS Health, one of the largest U.S. managers of drugbenefits, said it would give Gilead's hepatitis C treatmentpreferred status over AbbVie's drug, CNBC reported. ExpressScripts Holding Co, the largest U.S. drug benefitsmanager, gave AbbVie's drug a preferred status over Gilead'smedication two weeks ago.

** FORD MOTOR CO, $14.75, -3.97 pct

** FIAT CHRYSLER AUTOMOBILES NV, $11.15, -4.62 pct

** HONDA MOTOR CO, $28.98, -2.06 pct

The December U.S. sales of all three automakers fell shortof market estimates. Industry executives and analysts cautionedthat sales growth will slow this year after five years of rapidrecovery from the recession.

** KITE PHARMA INC, $67.95, +12.11 pct

Amgen Inc and Kite Pharma said they entered into adeal to develop and market cancer immunotherapies using Amgen'scancer targets and Kite's technology platform.

** STEREOTAXIS INC, $1.88, +22.08 pct

The U.S. Food and Drug Administration approved the medicaldevice maker's catheter device, Vdrive with catheter advancementsystem, for sale in the country.

The company also received an approval from JapanPharmaceuticals and Medical Devices Agency for Odyssey datamanagement products.

** CONATUS PHARMACEUTICALS INC, $10.064, +24.40 pct

The biotechnology company said it would present results fromthree clinical trials of its lead drug Emricasan on Thursday.Conatus said it would present results from a mid-stage study ofthe drug in patients with acute-on-chronic liver failure.

** ISIS PHARMACEUTICALS INC, $67.09, +8.97 pct

Johnson & Johnson will pay the biotech company up to$835 million for an option to license three drugs targetingautoimmune diseases in the bowel.

** CEMPRA INC, $24.78, +8.26 pct

The antibiotic drug developer moved a step closer toapproval for its lead antibiotic, solithromycin, after an oralversion of the potential blockbuster met the main goal in alate-stage trial.

** NATIONAL BANK OF GREECE SA, $1.67, -9.24 pct

Political uncertainty in Greece may force the EuropeanCentral Bank to start quantitative easing as debate around thepossibility of elections later this month resulting in thecountry leaving the euro zone picked up again.

Euro fell to $1.18605 in early Asian trading onMonday, its weakest level since March 2006.

** BREITBURN ENERGY PARTNERS LP, $7.1264, -6.60 pct

The oil and gas company said on Friday it expected 2015production of 19.5-20.7 million barrels of oil equivalent (boe),up from an estimated 14.1 million boe for 2014. Breitburnforecast oil and gas capital expenses to fall to $200 million in2015 from an estimated $375 million in 2014.

** CINEMARK HOLDINGS INC, $33.84, -3.07 pct

The movie theater chain's shares could rise more than 25percent over the next year, Barron's reported in its Jan. 5edition.

** ZIMMER HOLDINGS INC, $116.375, +3.36 pct

Analysts at J.P. Morgan upgraded the orthopaedic devicemaker's shares to "overweight" from "neutral" and raised theirprice target on it to $136 from $120 - the highest among 25brokerages covering the stock.

Zimmer could benefit from reduced dis-synergy risk andimproved industry pricing over time if Stryker Corp pursues and ultimately reaches an agreement with Smith & NephewPlc, the analysts wrote.

The stock touched its year-high of $117.19. (Compiled by Lehar Maan; Editing by Joyjeet Das)